X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1380) 1380
Publication (112) 112
Newsletter (25) 25
Book Review (10) 10
Book Chapter (7) 7
Book / eBook (2) 2
Conference Proceeding (2) 2
Magazine Article (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1259) 1259
male (671) 671
female (542) 542
index medicus (438) 438
adult (401) 401
agammaglobulinemia - complications (386) 386
agammaglobulinemia - drug therapy (329) 329
middle aged (308) 308
immunology (298) 298
child (295) 295
agammaglobulinemia (288) 288
x-linked agammaglobulinemia (269) 269
agammaglobulinemia - immunology (245) 245
adolescent (244) 244
child, preschool (207) 207
infant (186) 186
hypogammaglobulinemia (172) 172
aged (170) 170
agammaglobulinemia - diagnosis (156) 156
immunoglobulins, intravenous - therapeutic use (155) 155
agammaglobulinemia - therapy (151) 151
agammaglobulinemia - genetics (145) 145
common variable immunodeficiency (142) 142
animals (139) 139
immunodeficiency (135) 135
immunoglobulins (133) 133
agammaglobulinemia - etiology (124) 124
allergy (112) 112
pediatrics (109) 109
agammaglobulinemia - chemically induced (108) 108
intravenous immunoglobulin (107) 107
treatment outcome (106) 106
medicine, general & internal (102) 102
care and treatment (94) 94
health aspects (90) 90
infections (90) 90
immunoglobulin g (89) 89
hematology (88) 88
disease (87) 87
infectious diseases (87) 87
risk factors (83) 83
immunoglobulin g - blood (79) 79
internal medicine (77) 77
b-lymphocytes - immunology (76) 76
gamma-globulins - therapeutic use (75) 75
therapy (74) 74
infection (72) 72
research (71) 71
agammaglobulinemia - blood (69) 69
anti-bacterial agents - therapeutic use (68) 68
recurrence (68) 68
retrospective studies (67) 67
young adult (67) 67
mutation (66) 66
children (64) 64
immunoglobulin (62) 62
oncology (61) 61
time factors (61) 61
rituximab (60) 60
allergy and immunology (59) 59
patients (59) 59
t-lymphocytes - immunology (59) 59
protein-tyrosine kinases - antagonists & inhibitors (57) 57
drug therapy (56) 56
follow-up studies (56) 56
transplantation (56) 56
agammaglobulinemia - pathology (55) 55
immunoglobulins, intravenous - administration & dosage (55) 55
immunoglobulin g - analysis (54) 54
diagnosis (53) 53
immunologic deficiency syndromes - immunology (53) 53
mice (53) 53
diagnosis, differential (52) 52
analysis (51) 51
immunoglobulins, intravenous - adverse effects (51) 51
lymphocytes (51) 51
infant, newborn (50) 50
protein-tyrosine kinases - genetics (50) 50
syndrome (50) 50
primary immunodeficiency (49) 49
immunologic deficiency syndromes - complications (48) 48
abridged index medicus (47) 47
biomedicine (47) 47
common variable immunodeficiency - immunology (47) 47
genetic diseases, x-linked - drug therapy (46) 46
immunocompromised host (46) 46
immunologic deficiency syndromes - diagnosis (46) 46
immunologic deficiency syndromes - drug therapy (46) 46
patient (46) 46
chronic disease (45) 45
common variable immunodeficiency - complications (45) 45
pharmacology & pharmacy (45) 45
autoimmunity (44) 44
genetic diseases, x-linked - complications (44) 44
medicine & public health (43) 43
brutons tyrosine kinase (42) 42
immunoelectrophoresis (42) 42
immunologic deficiency syndromes - therapy (42) 42
medical microbiology (42) 42
rheumatology (42) 42
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1241) 1241
German (57) 57
French (43) 43
Japanese (16) 16
Polish (10) 10
Spanish (10) 10
Italian (8) 8
Russian (5) 5
Hebrew (4) 4
Hungarian (4) 4
Swedish (3) 3
Danish (2) 2
Romanian (2) 2
Chinese (1) 1
Croatian (1) 1
Czech (1) 1
Dutch (1) 1
Finnish (1) 1
Norwegian (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 06/2011, Volume 29, Issue 18, pp. 2493 - 2498
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 7/2010, Volume 107, Issue 29, pp. 13075 - 13080
Activation of the B-cell antigen receptor (BCR) signaling pathway contributes to the initiation and maintenance of B-cell malignancies and autoimmune diseases.... 
T lymphocytes | Animal models | Disease models | Gels | B lymphocytes | B cell lymphoma | Arthritis | Mice | Autoimmune diseases | Tumors | X-linked agammaglobulinemia | Lymphoma | COLLAGEN-INDUCED ARTHRITIS | THERAPY | RITUXIMAB | MULTIDISCIPLINARY SCIENCES | lymphoma | DOGS | FAMILY KINASES | BTK | RECEPTOR | DEPLETION | MICE | Arthritis, Experimental - drug therapy | Pyrazoles - therapeutic use | Humans | Benzofurans - administration & dosage | Benzofurans - pharmacology | Autoantibodies - biosynthesis | Pyrimidines - chemistry | Benzofurans - chemistry | Protein Kinase Inhibitors - chemistry | Pyrazoles - chemistry | Lymphoma, B-Cell - enzymology | Autoimmune Diseases - drug therapy | Disease Models, Animal | Lymphoma, B-Cell - drug therapy | Pyrazoles - pharmacology | B-Lymphocytes - enzymology | Benzofurans - therapeutic use | Autoimmune Diseases - enzymology | Administration, Oral | Pyrimidines - administration & dosage | Treatment Outcome | Pyrimidines - pharmacology | Receptors, Antigen, B-Cell - immunology | B-Lymphocytes - drug effects | Protein Kinase Inhibitors - administration & dosage | Pyrazoles - administration & dosage | Animals | B-Lymphocytes - immunology | Signal Transduction - drug effects | Lymphocyte Activation - drug effects | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Dogs | Protein Kinase Inhibitors - pharmacology | Protein-Tyrosine Kinases - antagonists & inhibitors | Tyrosine | Cell receptors | Models | Lymphomas | Research | Properties | Biological Sciences
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2016, Volume 374, Issue 4, pp. 323 - 332
Acalabrutinib is an irreversible inhibitor of Bruton's tyrosine kinase with greater specificity for the enzyme than the first-in-class agent, ibrutinib. It had... 
B-CELL RECEPTOR | MEDICINE, GENERAL & INTERNAL | ACTIVATION | IN-VIVO | X-LINKED AGAMMAGLOBULINEMIA | IBRUTINIB | BTK | PCI-32765 | TYROSINE KINASE INHIBITOR | LYMPHOMA | OPEN-LABEL | Recurrence | Benzamides - pharmacokinetics | Humans | Middle Aged | Pyrazines - administration & dosage | Male | Antineoplastic Agents - administration & dosage | Leukemia, Lymphocytic, Chronic, B-Cell - genetics | Protein Kinase Inhibitors - adverse effects | Diarrhea - chemically induced | Dose-Response Relationship, Drug | Benzamides - administration & dosage | Antineoplastic Agents - adverse effects | Female | Antineoplastic Agents - pharmacokinetics | Benzamides - adverse effects | Headache - chemically induced | Chromosome Deletion | Protein Kinase Inhibitors - pharmacokinetics | Administration, Oral | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Agammaglobulinaemia Tyrosine Kinase | Pyrazines - pharmacokinetics | Pyrazines - adverse effects | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Protein-Tyrosine Kinases - antagonists & inhibitors | Antimitotic agents | Treatment outcome | Usage | Care and treatment | Safety and security measures | Lymphocytic leukemia | Analysis | Clinical trials | Pharmacology | Dosage and administration | Pharmacokinetics | Antineoplastic agents | Tyrosine | Headache | Pharmacodynamics | Transformation | Chronic lymphatic leukemia | Inhibitor drugs | Leukemia | Diarrhea | Chromosome deletion | Lymphatic leukemia | Kinases | Lymphoma | Bruton's tyrosine kinase | Patients | Clonal deletion | Lymphomas | Safety | Drug therapy | Lymphocytosis | Protein-tyrosine kinase | Chromosome 17 | Index Medicus | Abridged Index Medicus
Journal Article
Scandinavian Journal of Immunology, ISSN 0300-9475, 08/2013, Volume 78, Issue 2, pp. 130 - 139
BTK and ITK are cytoplasmic tyrosine kinases of crucial importance for B and T cell development, with loss‐of‐function mutations causing X‐linked... 
POTENT INHIBITOR | BONE-MARROW | X-LINKED AGAMMAGLOBULINEMIA | CHRONIC LYMPHOCYTIC-LEUKEMIA | IMMUNOLOGY | BRUTONS-TYROSINE-KINASE | MICE LACKING | IBRUTINIB PCI-32765 | CELL-ACTIVATION | TEC FAMILY KINASES | ANTILEUKEMIC AGENT | Pyrazoles - therapeutic use | Agammaglobulinemia - genetics | Genetic Diseases, X-Linked - enzymology | Protein-Tyrosine Kinases - metabolism | Humans | Antineoplastic Agents - therapeutic use | Agammaglobulinemia - pathology | Lymphoma - drug therapy | Protein-Tyrosine Kinases - genetics | Agammaglobulinemia - drug therapy | Agammaglobulinemia - enzymology | Genetic Diseases, X-Linked - drug therapy | T-Lymphocytes - drug effects | Epstein-Barr Virus Infections - genetics | Lymphoma - enzymology | Genetic Diseases, X-Linked - genetics | Lymphoma - pathology | Gene Expression Regulation, Neoplastic - drug effects | Epstein-Barr Virus Infections - enzymology | Small Molecule Libraries - therapeutic use | Lymphoma - genetics | Epstein-Barr Virus Infections - drug therapy | Epstein-Barr Virus Infections - pathology | B-Lymphocytes - drug effects | B-Lymphocytes - immunology | Signal Transduction - drug effects | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Genetic Diseases, X-Linked - pathology | T-Lymphocytes - immunology | Inflammation - prevention & control | Autoimmunity - drug effects | Protein-Tyrosine Kinases - antagonists & inhibitors | Drugs | Autoimmunity | Care and treatment | Multiple myeloma | Lymphomas | Drug therapy | Health aspects | Phosphotransferases | Cancer
Journal Article
Journal Article
Journal Article